Lexicon Pharmaceuticals Inc
NASDAQ:LXRX

Watchlist Manager
Lexicon Pharmaceuticals Inc Logo
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
Watchlist
Price: 0.7734 USD -1.45% Market Closed
Market Cap: 279.6m USD
Have any thoughts about
Lexicon Pharmaceuticals Inc?
Write Note

Operating Margin
Lexicon Pharmaceuticals Inc

-4 037.4%
Current
-22 885%
Average
-7.9%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-4 037.4%
=
Operating Profit
-211.1m
/
Revenue
5.2m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
279.6m USD
-4 037%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
314.6B USD
28%
US
Amgen Inc
NASDAQ:AMGN
141.2B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
117.3B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.4B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
136.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.4B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36.2B EUR
-22%
Country US
Market Cap 279.6m USD
Operating Margin
-4 037%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 314.6B USD
Operating Margin
28%
Country US
Market Cap 141.2B USD
Operating Margin
19%
Country US
Market Cap 117.3B USD
Operating Margin
38%
Country US
Market Cap 105.4B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 136.4B AUD
Operating Margin
26%
Country US
Market Cap 78.4B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36.2B EUR
Operating Margin
-22%
No Stocks Found

Lexicon Pharmaceuticals Inc
Glance View

Market Cap
279.6m USD
Industry
Biotechnology

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 87 full-time employees. The company went IPO on 2000-04-07. The firm is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its pipeline includes Sotagliflozin, LX9211, and LX2761. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes, heart failure and chronic kidney disease. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The firm is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.

LXRX Intrinsic Value
0.5564 USD
Overvaluation 28%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-4 037.4%
=
Operating Profit
-211.1m
/
Revenue
5.2m
What is the Operating Margin of Lexicon Pharmaceuticals Inc?

Based on Lexicon Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of -4 037.4%.